- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01394510
Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
Effect of Anti-oxidants on Beta-cell Function in Humans
Insulin is secreted by cells in the pancreas called beta-cells. Beta-cell dysfunction is a critical feature of type 2 diabetes (T2DM). High glucose levels can exacerbate beta-cell dysfunction with oxidative stress proposed as a major mediator of this "glucotoxic" effect. High glucose levels have also been shown to contribute to vascular dysfunction and inflammation and these adverse responses decreased with the use of antioxidants. The hypothesis is that antioxidants improve beta-cell function in individuals with elevated glucose levels by decreasing oxidative stress. In this study the investigators will specifically test whether the antioxidant N-acetylcysteine (NAC) can improve beta-cell function in individuals with type 2 diabetes by decreasing oxidative stress.
This study will be a dose finding study to determine the tolerability of 600 mg versus 1200 mg twice a day of NAC and the effects on beta-cell function, glucose tolerance and oxidative stress markers in persons with type 2 diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Beta-cell dysfunction is a critical feature of type 2 diabetes (T2DM). High glucose levels can exacerbate beta-cell dysfunction with oxidative stress proposed as a major mediator of this "glucotoxic" effect. High glucose levels have also been shown to contribute to vascular dysfunction and inflammation and these adverse responses decreased with the use of antioxidants. The hypothesis is that antioxidants improve beta-cell function in individuals with elevated glucose levels by decreasing oxidative stress. In this study the investigators will specifically test whether the antioxidant N-acetylcysteine (NAC) can improve beta-cell function in individuals with type 2 diabetes by decreasing oxidative stress.
This initial study will be a dose finding study to determine the tolerability of 600 mg versus 1200 mg twice a day of NAC and the effects of NAC treatment on beta-cell function, glucose tolerance and oxidative stress markers in persons with type 2 diabetes. Study procedures will include a fasting urine sample and performance of a 2 hour 75 gram oral glucose tolerance test at baseline, after 2 weeks on 600 mg twice daily NAC and again after 2 more weeks on 1200 mg NAC twice a day.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound Health Care System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes
Exclusion Criteria:
- Pregnant or lactating females
- Uncontrolled diabetes mellitus with severe hyperglycemia (hemoglobin A1C ≥ 9%)
- Patients with diabetes mellitus who are taking insulin or glucose-lowering agents other than metformin
- Chronic oral or parenteral corticosteroid treatment (>7 consecutive days of treatment) within 8 weeks prior to screening
- Use of human immunodeficiency virus (HIV) protease inhibitors or niacin
- Chronic inflammatory diseases or use of anti-inflammatory drugs.
- Thyroid abnormalities (thyroid-stimulating hormone [TSH] <0.5 or >5 µU/ml)
- Creatinine >1.5 in men and >1.3 mg/dl in women
- History of dysphagia, gastroparesis, gastric ulcer, malabsorption, swallowing disorders or intestinal motility disorder
- Gastroesophageal reflux disease (heartburn) requiring treatment.
- Active cancer
- Clinical hepatic disease or alanine aminotransferase (ALT) greater than ≥ 1.5 times upper limit of normal within 60 days preceding the first dose of the study drug
- Weight loss of >5% body weight within the last 6 months, or starting an intensive exercise program within 4 weeks of study initiation
- Smoke or use tobacco
- Excessive alcohol consumption (>2 drinks a day)
- Use of any investigational drug in the last 30 days
- Anemia (hematocrit <33%), donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks prior to screening
- Employment by the research center
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: N-acetylcysteine dose study
Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks.
Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
|
600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Urine F2 Alpha Isoprostane Levels
Time Frame: 4 weeks
|
Change in fasting urine isoprostane levels at 4 weeks vs baseline as a marker of oxidative stress
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve for Glucose (AUCg)
Time Frame: 4 weeks
|
Change in AUCg from 0-120 minutes during the oral glucose tolerance test at 4 weeks compared to baseline
|
4 weeks
|
Oral Disposition Index
Time Frame: 4 weeks
|
The change in the oral disposition index defined was the change in the early insulin response divided by the change in glucose from 0-30 minutes during the oral glucose tolerance test divided by fasting insulin.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristina Utzschneider, MD, VA Puget Sound Health Care System
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- NACStudy001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on N-acetylcysteine
-
Medical University of South CarolinaCompleted
-
Institut d'Anesthesiologie des Alpes MaritimesCompleted
-
Rajavithi HospitalCompletedChemotherapy-induced Peripheral NeuropathyThailand
-
University of Sao Paulo General HospitalActive, not recruiting
-
Indiana UniversityBioAdvantex PharmaCompletedHIV | Endothelial Dysfunction | Oxidative StressUnited States
-
Assaf-Harofeh Medical CenterUnknownChronic Kidney Diseases | General AnesthesiaIsrael
-
Assistance Publique - Hôpitaux de ParisTerminatedSelenoprotein N-related MyopathyFrance
-
VA Office of Research and DevelopmentNational Center for Complementary and Integrative Health (NCCIH)CompletedDiabetic Nephropathy | Proteinuria | Oxidative StressUnited States
-
University of ChicagoNational Institute on Drug Abuse (NIDA); University of MinnesotaCompletedTobacco Use Disorder | GamblingUnited States
-
Universidade Estadual de LondrinaUnknownInflammation | Tobacco Smoking | Oxidative StressBrazil